tetano
Editor, Senior Moderator
Vaccine
. 2024 Mar 19:S0264-410X(23)01421-4.
doi: 10.1016/j.vaccine.2023.11.057. Online ahead of print. Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity
Igor Krasilnikov[SUP] 1 [/SUP], Artur Isaev[SUP] 2 [/SUP], Milana Djonovic[SUP] 3 [/SUP], Alexander Ivanov[SUP] 4 [/SUP], Ekaterina Romanovskaya-Romanko[SUP] 5 [/SUP], Marina Stukova[SUP] 6 [/SUP], Vitaly Zverev[SUP] 7 [/SUP]
Affiliations
The development of an effective combined vaccine represents a crucial strategy for preventing outbreaks of infectious diseases and reducing the burden on healthcare resources. Developing a combined vaccine against both influenza and the coronavirus is a promising approach, but it is still in the early stages of development. This paper reports on a novel combined pentavalent candidate vaccine that has shown promising results in mice, with statistically significant differences in mean antibody titer against the coronavirus and the influenza antigens compared to placebo. We have shown that the coronavirus antigen is capable of inducing an immune response autonomously, regardless of the presence of the influenza antigens in a combined vaccine. On the other hand, the presence of the coronavirus antigen in a combined vaccine showed to enhance the immune response against some of the studied influenza antigens, suggesting that these antigens may act in synergy and elicit an enhanced immune response. The absence of dose-dependent difference in mean antibody titer within the same antigenic groups of vaccine preparations suggested that even small amounts of the coronavirus and the influenza antigens could induce an immune response just as good as high-dose vaccine preparations, which certainly has important safety and cost implications. The vaccine is soon to be ready for clinical trials and mass production.
Keywords: Adjuvant; Betulin; COVID-19 vaccine; Combined vaccine; Flu vaccine; Pentavalent vaccine.
. 2024 Mar 19:S0264-410X(23)01421-4.
doi: 10.1016/j.vaccine.2023.11.057. Online ahead of print. Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity
Igor Krasilnikov[SUP] 1 [/SUP], Artur Isaev[SUP] 2 [/SUP], Milana Djonovic[SUP] 3 [/SUP], Alexander Ivanov[SUP] 4 [/SUP], Ekaterina Romanovskaya-Romanko[SUP] 5 [/SUP], Marina Stukova[SUP] 6 [/SUP], Vitaly Zverev[SUP] 7 [/SUP]
Affiliations
- PMID: 38508927
- DOI: 10.1016/j.vaccine.2023.11.057
The development of an effective combined vaccine represents a crucial strategy for preventing outbreaks of infectious diseases and reducing the burden on healthcare resources. Developing a combined vaccine against both influenza and the coronavirus is a promising approach, but it is still in the early stages of development. This paper reports on a novel combined pentavalent candidate vaccine that has shown promising results in mice, with statistically significant differences in mean antibody titer against the coronavirus and the influenza antigens compared to placebo. We have shown that the coronavirus antigen is capable of inducing an immune response autonomously, regardless of the presence of the influenza antigens in a combined vaccine. On the other hand, the presence of the coronavirus antigen in a combined vaccine showed to enhance the immune response against some of the studied influenza antigens, suggesting that these antigens may act in synergy and elicit an enhanced immune response. The absence of dose-dependent difference in mean antibody titer within the same antigenic groups of vaccine preparations suggested that even small amounts of the coronavirus and the influenza antigens could induce an immune response just as good as high-dose vaccine preparations, which certainly has important safety and cost implications. The vaccine is soon to be ready for clinical trials and mass production.
Keywords: Adjuvant; Betulin; COVID-19 vaccine; Combined vaccine; Flu vaccine; Pentavalent vaccine.